Shen Michelle, Liu Shiqin, Stoyanova Tanya
Department of Radiology, Canary Center at Stanford for Cancer Early Detection, Stanford University USA.
Am J Clin Exp Urol. 2021 Feb 15;9(1):73-87. eCollection 2021.
Prostate cancer remains the second leading cause of cancer-associated deaths amongst American men. Trop2, a cell surface glycoprotein, correlates with poor clinical outcome and is highly expressed in metastatic, treatment-resistant prostate cancer. High levels of Trop2 are prognostic for biochemical recurrence. Trop2 regulates tumor growth and metastatic ability of prostate cancer. Moreover, overexpression of Trop2 drives the transdifferentiation to neuroendocrine phenotype in prostate cancer. In addition, Trop2 is overexpressed across epithelial cancers and has emerged as a promising therapeutic target in various solid epithelial cancers. The FDA (Food and Drug Administration) recently approved the use of a Trop2-targeting ADC (antibody-drug conjugate), Sacituzumab Govitecan (IMMU-132), for metastatic, triple-negative breast cancer with at least two prior therapies. Here, we review the role of Trop2 in prostate tumorigenesis and its potential as a promising biomarker and therapeutic target for prostate cancer.
前列腺癌仍然是美国男性癌症相关死亡的第二大主要原因。Trop2是一种细胞表面糖蛋白，与不良临床结果相关，在转移性、耐治疗性前列腺癌中高度表达。Trop2高水平预示着生化复发。Trop2调节前列腺癌的肿瘤生长和转移能力。此外，Trop2的过表达驱动前列腺癌向神经内分泌表型转分化。此外，Trop2在各种上皮癌中均有过表达，并已成为各种实体上皮癌中有前景的治疗靶点。美国食品药品监督管理局（FDA）最近批准使用一种靶向Trop2的抗体药物偶联物（ADC）——戈沙妥珠单抗（IMMU-132），用于治疗接受过至少两种先前疗法的转移性三阴性乳腺癌。在此，我们综述了Trop2在前列腺肿瘤发生中的作用及其作为前列腺癌有前景的生物标志物和治疗靶点的潜力。
